CAS: 4338-47-0; (2R,3R,4S,5R)-2-(6-((Furan-2-Ylmethyl)Amino)-9H-Purin-9-yl)-5-(Hydroxymethyl)Tetrahydrofuran-3,4-Diol

上下游产品

CAS号4753-68-8 2-furanylmethan... | CAS号2004-06-0 6-氯嘌呤核苷 | CAS号98-01-1 糠醛 | CAS号58-61-7 腺苷 | CAS号617-89-0 糠胺 | CAS号105499-44-3 2,3,5-tri-O-ace... | CAS号1121-47-7 2-呋喃甲醛肟 | CAS号342-69-8 6-(甲硫基)-9-β-D-呋... | CAS号7387-58-8 [5-(6-acetamido... | CAS号525-79-1 6-糠氨基嘌呤 | CAS号18646-11-2 α-D-ribofuranos...

📜6-N-2',3',5'-Tri-O-Tetraacetyladenosine置于甲醇,氨,三苯基膦,偶氮二甲酸二乙酯体系中,用 四氢呋喃 作为反应溶剂,化学反应 48.0H,反应生成 激动素核苷
参考文献:N6-乙酰基-2',3',5'-三-O-乙酰腺苷;区域选择性n6-烷基化的便捷"缺失"底物
标题:N6-乙酰基-2',3',5'-三-O-乙酰腺苷;区域选择性n6-烷基化的便捷"缺失"底物
摘要:在咪唑存在下,在室温下用甲醇对五乙酰基腺苷2进行选择性的n-脱乙酰基化反应,建立了一种简单有效的n 6-乙酰基2',3',5'-Tri-O-乙酰腺苷(1)路线. .利用2和1的粗混合物,通过腺苷与乙酸酐在吡啶中在升高的温度下反应制备的混合物,详细说明了1的制备合成.从腺苷开始,总产率为1,为80-85%.结果表明1是选择性n 6的便捷底物-烷基化.该研究揭示了在1与活化的烷基卤化物的碱促进反应和1与醇的光延反应中相同的区域选择性.制备了一系列的n 6-烷基腺苷5A-F.通过使用核苷磷酸化酶和碱性磷酸酶的组合对母体核苷衍生物5B,D,E进行酶促转化来制备细胞分裂素6B,D,E. 细胞分裂素-腺苷衍生物-N 6-烷基化-区域选择性-Mitsunobu反应-核苷磷酸化酶
DOI:10.1055/s-0030-1260090

专利信息

专利号:US-2024207302-A1
优先权日:2021-04-01
标 题 :Antiviral compounds, methods for the manufacturing of compounds, antiviral pharmaceutical composition, use of the compounds and method for the oral treatment of coronavirus infection and related diseases thereof
发明人：CALIXTO JOãO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO
权利人:CALIXTO JOAO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO
摘要:The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-COV-2 and MHIV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-COV-2 and of patients with COVID-19, individual infected with SARS-COV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-COV-2 was greatly enhanced by inhibiting the 3′-5′-exonuclease. Synergistic results of the compounds according to the present invention were obtained from the combination with repurposed drugs.

专利号:US-2023241088-A1
优先权日:2022-01-17
标 题 :Composition for preventing or treating lung cancer comprising ortho-topolin riboside as active ingredient
发明人：CHOI HYUNG-KYOON; LEE HWANHUI
权利人:CHUNG ANG UNIV INDUSTRY ACADEMY COOPERATION FOUNDATION
摘要:The present disclosure relates to a composition for preventing or treating lung cancer, including ortho topolin riboside (oTR) as an active ingredient, wherein oTR showed the highest cytotoxicity among all tested compounds against NSCLC cells, oTR reduced synthesis of amino acid and pyrimidine as well as glycolytic function in NSCLC cells and xenograft tumors.